Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?

Like
Comment
Favorite

Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?

Motley Fool10-24

Summit Therapeutics stock shot higher this September in response to outstanding clinical-trial results. The company's lead candidate is a cancer therapy that's already approved in China. ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Report

Comment

No comments yet

Most Discussed

7x24

All

Terms and Conditions·Privacy Policy

Company: TTMF Limited. Tech supported by Xiangshang Yixin.

Email：uservice@ttm.financial

{"i18n":{"language":"en_US"},"data":{"share":"https://ttm.financial/m/news/2477505752?lang=en_US&edition=fundamental","thumbnail":"https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795021%2Fboard-room-chart-getty.jpg&op=resize&w=165&h=104","is_english":true,"pubTime":"2024-10-24 17:13","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2477505752","market":"fut","top_or_hot":-1,"title":"Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?","media":"Motley Fool","content":"<div>\n<p>Summit Therapeutics stock shot higher this September in response to outstanding clinical-trial results.\n\n\n\n\n\n\n\nThe company's lead candidate is a cancer therapy that's already approved in China.\n\n\n\n\n\n\n...</p>\n\n<a href=\"https://www.fool.com/investing/2024/10/24/up-over-600-in-2024-can-summit-therapeutics-stock/\">Source Link</a>\n\n</div>\n","source":"fool_stock","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUp Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-10-24 17:13 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.fool.com/investing/2024/10/24/up-over-600-in-2024-can-summit-therapeutics-stock/><strong>Motley Fool</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Summit Therapeutics stock shot higher this September in response to outstanding clinical-trial results.\n\n\n\n\n\n\n\nThe company's lead candidate is a cancer therapy that's already approved in China.\n\n\n\n\n\n\n...</p>\n\n<a href=\"https://www.fool.com/investing/2024/10/24/up-over-600-in-2024-can-summit-therapeutics-stock/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU1037948897.HKD","symbol_name":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","start_time":0,"source_url":"https://www.fool.com/investing/2024/10/24/up-over-600-in-2024-can-summit-therapeutics-stock/","article_id":"2477505752","we_media_id":null,"thumbnails":["https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F795021%2Fboard-room-chart-getty.jpg&op=resize&w=165&h=104"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2477505752","pubTimestamp":1729761180,"columns":[],"sourceInfo":{"source_id":"fool_stock","name":"Motley Fool"},"weMediaInfo":null,"summary":"This drugmaker's lead candidate could become a top-selling cancer therapy.","collect":0,"end_time":0,"defaultTopTitle":"fool.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU1037948897.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (HKD) INC","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","BK4211":"区域性银行","LU1934455277.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"AD\" (USD) INC","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU0208291251.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) INC","LU1037948541.HKD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (HKD) ACC","IE00BSNM7G36.USD":"NEUBERGER BERMAN SYSTEMATIC GLOBAL SUSTAINABLE VALUE \"A\" (USD) ACC","LU0234572021.USD":"高盛美国核心股票组合Acc","LU1917777945.USD":"安联专题基金Cl AT Acc","IE00BLSP4239.USD":"Legg Mason ClearBridge - Tactical Dividend Income A Mdis USD Plus","LENZ":"Therapeutics","LU1934455194.USD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (USD) ACC","BK4588":"碎股","LU0965509010.AUD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (AUDHDG) INC","LU0058720904.USD":"联博国际健康护理基金A","LU1934455863.HKD":"AB SICAV I LOW VOLATILITY TOTAL RETURN EQUITY PORT \"A\" (HKD) ACC","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","LU0320765489.SGD":"FTIF - Franklin Mutual US Value A Acc SGD","LU1066051811.HKD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM2\" (HKD) INC","LU0006306889.USD":"SCHRODER ISF US LARGE CAP \"A\" (USD) INC AV","MRK":"默沙东","LU0985320562.USD":"NORDEA 1 GLOBAL STARS EQUITY \"BP\" (USD) ACC","LU1066053197.SGD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AM3\" (SGDHDG) INC","LU0106261372.USD":"SCHRODER ISF US LARGE CAP \"A\" ACC","LU0965509283.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"AD\" (SGDHDG) INC","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","LU0861579265.USD":"联博低波幅策略股票基金A","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU0203347892.USD":"SCHRODER ISF QEP GLOBAL ACTIVE VALLUE \"A\" (USD)  INC AV","LU0070302665.USD":"FRANKLIN MUTUAL U.S. VALUE \"A\" (USD) ACC","IE000M9KFDE8.USD":"NEUBERGER BERMAN US LARGE CAP VALUE \"A\" (USD) ACC","LU1291159041.SGD":"CPR Invest - Global Silver Age A2 Acc SGD-H","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","LU0965509101.SGD":"AB LOW VOLATILITY EQUITY PORTFOLIO \"A\" (SGDHDG) ACC","LU1066051225.USD":"HSBC GIF GLOBAL EQUITY VOLATILITY FOCUSED \"AC\" (USD) ACC","LU1585245621.USD":"EASTSPRING INV GLOBAL LOW VOLATILITY EQUITY FUND \"A\" (USD) ACC B","IE00B4R5TH58.HKD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (HKD) ACC","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","IE00BBT3K403.USD":"LEGG MASON CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A(USD) ACC","LU1116320901.HKD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A6\" (HKD) INC","LU0238689110.USD":"贝莱德环球动力股票基金","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","BK4534":"瑞士信贷持仓","LU0265550946.USD":"BGF SYSTEMATIC GLOBAL ENHANCED EQUITY YIELD \"A5\" (USD) INC","BK4585":"ETF&股票定投概念","SMMF":"Summit Financial Group","BK4533":"AQR资本管理(全球第二大对冲基金)","IE00BN8TJ469.HKD":"FTGF CLEARBRIDGE TACTICAL DIVIDEND INCOME \"A\" (HKD) INC"},"translate_title":"2024年上涨超过600%，Summit Therapeutics股价能否继续上涨？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SMMF":1,"LENZ":1,"MRK":0.9},"content_text":"Summit Therapeutics stock shot higher this September in response to outstanding clinical-trial results.\n\n\n\n\n\n\n\nThe company's lead candidate is a cancer therapy that's already approved in China.\n\n\n\n\n\n\n\nSummit's market valuation implies a great deal of success that's a long way from guaranteed.\n\nTo say this has been a big year for Summit Therapeutics (SMMT -2.72%) would be a huge understatement. The stock has risen over 600% since the end of 2023, thanks to surprisingly positive trial results for a cancer therapy called ivonescimab.The stock market has been pushing up Summit's stock price because there's a chance that ivonescimab could unseat Merck's Keytruda as the world's top-selling cancer treatment. Keytruda racked up a stunning $25 billion in sales last year, so there's a lot to be gained if Summit's candidate continues to succeed.Summit Therapeutics is on the right path, but it could be too early to predict buckets of incoming revenue. Its candidate isn't even approved in the territories where Summit intends to sell it.Why Summit Therapeutics stock soaredDespite having no products to sell, Summit's market cap shot above $23 billion in September after investors saw interim results of the Harmoni-2 trial. The study assembled hundreds of newly diagnosed lung cancer patients in China and treated them with either Keytruda or ivonescimab. Measurements taken at a planned interim checkup showed patients randomized to receive ivonescimab were 49% less likely to show signs of disease worsening.Human immune cells come with programmed death (PD-1) receptors as a safety feature that shuts down attacks when they spill over and affect healthy tissues. Tumor cells exploit this checkpoint to evade immune attacks before they begin. Keytruda, Opdivo, and Tencentriq are all blockbuster drugs that shrink tumors by inhibiting the PD-1 checkpoint.Ivonescimab is an interesting new double-sided protein that inhibits the PD-1 checkpoint, plus it blocks vascular endothelial growth factor (VEGF) from increasing a tumor's blood supply. Summit's stock price has soared because investors think it can become the new standard of care for first-line lung cancer patients.Lung cancer isn't the most common malignancy but claims the most lives. For cancer therapy developers, first-line indications are precious because these patients tend to stay on therapy much longer than folks who have already relapsed.In May, ivonescimab became the first PD-1/VEGF bispecific antibody to earn approval when Chinese regulators approved it to treat a genetically defined group of lung cancer patients. Summit licensed rights to its lead candidate from a Chinese company named Akeso. Unfortunately, the U.S. Food and Drug Administration (FDA) will not approve new cancer therapies without successful results from a trial with plenty of North American volunteers.Summit recently completed enrollment of a phase 3 trial with second-line lung cancer patients based in the U.S. If adding ivonescimab to standard chemotherapy improves patients' odds of survival, as expected, the stock could soar.Incoming competition?Ivonescimab is the most advanced PD1/VEGF bispecific antibody but isn't the only one in clinical-stage testing. Last November, BioNTech (BNTX 0.09%) licensed BNT327 from a clinical-stage company called Biotheus.In a phase 2 trial, a combination of standard chemotherapy plus BNT327 shrank tumors for 54.7% of lung cancer patients who progressed after their first treatments.Ivonescimab could eventually compete with Instil Bio (TIL -5.27%) and its China-based partner ImmuneOnco Biopharmaceuticals. Together, the pair are developing an experimental PD1/VEGF treatment called IMM2510. In the U.S., Instil intends to begin midstage clinical studies with lung cancer and triple-negative breast cancer patients by the end of the year.Time to buy?Stocks don't get much riskier than Summit Therapeutics. At recent prices, the pre-commercial company boasts a $14.6 billion market cap. That's a lot to pay for a clinical-stage drugmaker with no recurring revenue yet.In early 2023, it handed Akeso $500 million upfront for exclusive rights to ivonescimab outside of China. Akeso is still eligible to receive up to $4.5 billion in potential milestone payments, plus a royalty percentage in the low double-digits.Commercial-stage biotech stocks generally trade for mid-single-digit multiples of annual revenue. When you add up the milestones and royalties that Summit could owe Akeso, it looks like the market is already pricing in a speedy FDA approval and a rapid ascent to several billion in annual sales.Summit Therapeutics stock could produce market-beating gains, but only if ivonescimab continues producing dramatic clinical-trial success stories. Starting a new position at recent prices would be a little too risky right now. It's probably best to wait for more data or a lower market valuation.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"hasMoreComments":false,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false}}